senotherapy senotherapy senotherapy is an early-stage basic research field for development of possible therapeutic agents and strategies to specifically target cellular senescence, an altered cell state associated with ageing and age-related diseases. the name derives from intent of the proposed anti-aging drug to halt "senescence". as of 2019, much of the research remains preliminary and there are no drugs approved for this purpose. types senotherapeutics include: geroprotectors – agents/strategies which prevent or reverse the senescent state by preventing triggers of cellular senescence, such as dna damage, oxidative stress, proteotoxic stress, telomere shortening (i.e. telomerase activators). sasp inhibitors – agents interfering with pro-inflammatory senescence-associated secretory phenotype (sasp) production, including: glucocorticoids as potent suppressors of selected components of the sasp statins such as simvastatin, that can reduce the expression of pro-inflammatory cytokines (il-6, il-8, and mcp-1) jak1/2 inhibitors such as ruxolitinib nf-κb and p38 inhibitors il-1α blockers mitochondrial depleters in the case of impaired mitophagy senolytics – small molecules that specifically induce cell death in senescent cells, targeting survival pathways and anti-apoptotic mechanisms, antibodies and antibody-mediated drug delivery medications. unlike sasp inhibitors, senolytics can be effective by intermittent rather than continuous application. senomorphics – small molecules that suppress senescent phenotypes without cell killing gene therapy strategies – edit the genes of the cells of an organism in order to increase their resistance to aging, senile diseases and to prolong the life of the organism